The race against time for genetic testing results in motor neurone disease (MND) has seen a significant turnaround, with wait times dropping from 18 months to around three months, according to research by the MND Association. This remarkable improvement is a testament to the power of advocacy and collaboration, as the Association worked tirelessly with NHS England’s Genomic Medicine Service to address the pressing issue of delayed genetic testing. But what does this mean for patients and the future of MND care? Let's delve into the details and explore the implications of this breakthrough.
A Year of Advocacy and Results
Since early 2025, the MND Association has been at the forefront of raising awareness about the long wait times for genetic testing results. Their efforts included advocating for fast-tracking MND tests and proposing an early SOD1 reporting system in areas with longer wait times. This proactive approach has paid off, as evidenced by the recent survey of 24 MND Association-funded Care Centres and Networks in March 2026. The results are nothing short of remarkable.
The Impact of Genetic Testing
Genetic testing plays a crucial role in the lives of people with MND, particularly those with a family history of the condition (inherited MND). It provides clarity around diagnosis, helps determine eligibility for research and targeted treatments, and enables individuals and their families to plan for the future. For instance, tofersen, a drug currently being appraised by NICE for prescribing by the NHS, has shown promise in slowing and even halting the progression of MND in individuals with a specific inherited type caused by a change in their SOD1 gene.
The Early Reporting System
One of the key initiatives that has contributed to the reduction in wait times is the early reporting system. This system, already used for other tests, allows labs to report positive SOD1 results sooner while the full genetic analysis continues. Its implementation in areas with longer wait times has been instrumental in facilitating access to tofersen, ensuring that patients can discuss treatment options with their medical team more promptly.
Looking Ahead
While the current guidelines state that genetic testing results should be shared within 84 days, the MND Association believes there is room for improvement. They are working with NHS England, clinicians, and people affected by MND to understand how genetic testing can be completed even more quickly and how to ensure that individuals outside of care center areas can access testing. This includes supporting the expansion of genomics education to build confidence among healthcare professionals and exploring the use of artificial intelligence to meet increasing demand within the genomics workforce.
The Broader Implications
The reduction in wait times for genetic testing results is not just a victory for the MND community; it has broader implications for healthcare systems and patient care. It highlights the importance of advocacy and collaboration in addressing complex healthcare issues. Moreover, it underscores the need for continuous improvement and innovation in healthcare services, particularly in rare diseases like MND. As we look to the future, it is essential to build on this momentum and continue to push for better access to genetic testing and precision medicine.
In conclusion, the turnaround in genetic testing results for MND is a significant step forward, offering hope and clarity to patients and their families. It is a testament to the power of advocacy and collaboration, and it serves as a reminder that with determination and innovation, we can make a difference in the lives of those affected by this devastating disease. As we move forward, let's continue to support and advocate for the MND community, ensuring that everyone has access to the care and support they need.
